Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Table 1

Demographic data of the patients.

Sex

Eye

Anti-VEGF

GA (weeks)

BW (g)

PMA (weeks)

Zone

Stage

Plus disease

Rubeosis iridis

Corrected age (months)

CYL (diopters)

SE (diopters)

F

OU

R

27

715

37

2/2

3/3

+/+

−/−

32

−1.750/−0.500

−0.125/0.000

M

OU

R

29

1402

40

3/3

3/3

+/+

−/−

36

−0.750/−1.250

0.125/−0.625

M

OU

R

25

832

34

2/2

3/3

−/−

−/−

35

−1.250/−0.500

−1.375/−1.250

M

OU

R

31

1350

36

2/2

3/3

+/+

−/−

30

−2.000/−1.250

−0.750/−0.625

M

OU

R

26

1138

35

22/

3/3

+/+

−/−

36

−0.750/−0.750

0.125/0.625

F

OU

R

26

521

39

2/2

3/3

+/+

−/−

37

−1.000/−0.750

1.000/0.375

M

OU

R

28

1115

39

2/2

3/3

+/+

−/−

31

−0.250/−1.000

0.125/0.250

F

OU

R

30

969

36

2/2

3/3

+/+

−/−

35

−0.500/−1.000

−0.500/−0.250

F

OU

R

25

758

35

2/2

3/3

+/+

−/−

38

−1.250/−2.000

0.875/0.250

F

OU

R

24

537

33

1/1

3/3

+/+

−/−

31

−0.750/−1.750

0.375/0.125

F

OU

R

26

507

33

1/1

3/3

+/+

+/+

39

−0.500/−1.500

0.500/1.000

F

OU

R

24

554

32

1/1

3/3

+/+

−/−

35

−3.750/−3.500

−3.125/−3.000

M

OU

R

24

732

40

1/2

3/3

+/+

−/−

37

−0.250/−0.250

1.625/1.125

M

OU

B

24

839

36

2/2

3/3

+/+

−/−

33

−0.750/−0.750

1.875/1.625

F

OD

B

26

780

33

2

3

+

—

37

−1.000

0.000

F

OU

B

25

720

36

2/2

3/3

+/+

−/−

34

−0.750/−0.500

2.625/2.250

M

OU

B

27

826

40

2/2

3/3

+/+

−/−

32

−1.500/−10.250

−0.250/−0.125

F

OU

B

24

686

35

2/2

3/3

+/+

−/−

37

−1.250/−0.750

−0.875/−7.875

M

OU

B

30

1247

35

2/2

3/3

+/+

−/−

35

−0.750/−0.500

0.375/−0.500

M

OS

B

28

974

46

2

3

+

—

34

−0.500

−0.250

M

OU

B

28

1039

38

2/2

3/3

+/+

−/−

35

−1.750/−1.500

−11.625/−7.750

M

OU

B

24

729

39

2/2

3/3

+/+

−/−

36

−2.000/−2.000

2.000/4.250

F

OU

B

26

724

35

2/2

3/3

+/+

+/+

36

−0.750/−0.750

2.125/2.375

F

OU

B

28

1060

36

2/2

3/2

+/+

−/−

38

−2.750/−1.500

−0.375/0.500

F

OD

B

27

954

42

2

3

+

—

37

−1.000

2.000

F

OU

B

25

751

35

2/2

2/2

+/+

−/−

34

−0.750/−0.500

0.125/0.250

F

OD

B

25

569

38

2

3

+

—

37

−1.750

0.375

F

OU

B

26

910

37

2/2

3/3

+/+

−/−

35

−2.500/−3.000

1.000/1.250

M

OU

B

28

1003

40

2/2

3/3

+/+

−/−

37

−0.500/−0.500

1.000/1.000

M

OU

B

32

1150

43

2/2

3/3

+/+

−/−

32

0.000/0.000

1.250/1.250

F

OU

B

32

1023

36

2/2

3/3

+/+

−/−

32

0.000/−1.250

0.750/0.375

F

OU

B

28

1120

32

2/2

3/3

+/+

−/−

39

−3.500/−3.250

−5.250/−12.125

M

OU

B

27

934

35

2/2

3/3

+/+

−/−

35

−3.750/−3.000

−5.375/−1.500

B: bevacizumab; BW: birth weight; CYL: cylinder; F: female; GA: gestational age; M: male; OD: right eye; OS: left eye; OU: both eyes; PMA: postmenstrual age; R: ranibizumab; SE: spherical equivalent.